Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RVPH breakoutttttt
(RVPH)UP 12%+ could explode again like it did in April from $4 to $10
$AWX 4.35 -float 2m -MC 17 m..
$ENSV $1.43-MC 15m -float 8m-heavily shorted = next potential mega MEME play
(ENSV)$1.43-float 8m..HOT gem for the coming days
(ENSV)$1.40-float 8 movinggggggg about to explodeeee
ENSV now $1.41 BREAKOUT imminent
(ENSV) $1.37-float 8 m-nice accumulation ongoing could explode anytime now
(ENSV)$1.30-float 8m--MC $14 m--HEAVILY shorted = NEW Mega MEME stock with potential 1000% upsideee...LIFETIME OPP guys
(ENSV) $1.37 now green ..only 8 m float and low valuation of $14 million has potential to be the next NURO guys
(ENSV)$1.30-float 8m- heavily shorted = under radar stock ,next potential 10 bagger gem guys
(ENSV)$1.30-float 8m- heavily shorted = under radar stock
(APLIF)$0.52--Covid PHASE 3 readout expected THIS Quarter /Drug partnered with Dr Reddy /Market cap only $32 m / UNKNOWN stock = Positive data could push this stock to $4-5 very fast ..GLTA
"We are encouraged that an independent Data and Safety Monitoring Board has recommended continuation without modification of Appili’s ongoing Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating Avigan®/Reeqonus™ (favipiravir). We look forward to the completion of the PRESECO trial and are hopeful that Avigan/Reeqonus will emerge as one of the first prescription oral medicine for newly diagnosed patients with COVID-19," continued Dr. Balboni."
(AWX)float 2m about to BREAKOUT ..market cap only 17 m
(AWX)$4.40-Book Value $9.70--float 2 m = Could run like NURO
AWX =$4.40--float 2 m=Next NURO
(ERYP)$4.40 RUNNINGGGGGGG...Market cap $115 ma low priced under radar Cancer Drug company which could have 2 HUGE cancer drug approved by next year ..a potential $50 stock trading at laughable 4 bucks
“We are encouraged by the interactive dialogue with the agency, and grateful for the feedback and guidance we received on a potential path to approval,” said Gil Beyen, CEO of ERYTECH. “This is an important milestone for ERYTECH as it advances our lead product candidate eryaspase as an alternative treatment for ALL patients with hypersensitivity to PEG-asparaginase, while our Phase 3 trial in second line pancreatic cancer is nearing completion. If all goes well, we could be in a position to make this product candidate available to ALL and pancreatic cancer patients in the course of next year.”
OCUP & AWX both are very low priced low floater with big upside
(AWX)$4.30--Book Value $9.70--Float 2 m..next low float bomb to explodeeee
AWX next NURO ..AWX has low valuation of $17 m--Book Value of $9.70 which is more than 50% higher than share price of $4.40 and only 3.5 outstanding shares
AWX better than NURO ..its profitable and has less outstanding shares .AWX trading at $4.40 while Book value is at $9.70
(AWX)$4.30-Book Value $9.70 -Float 2 m -Market Cap $16 m --Profitable company =Next low float BOMB to EXPLODE
(AWX)float 2 m.VS.(NURO) Float 3 m ..AWX is cheaper has less outstanding shares and its a profitable company .. If NURO can run to $25 then AWX should do that as well
(AWX)$4.30--Book Value $9.70-Float 2m--Profitable Company=Next low float BOMB to EXPLODEEEEE
(AWX) Float 2 m about to EXPLODEEEEEE
(AWX)$4.30-Book Value $9.70 -Float 2 m -Market Cap $16 m --Profitable company =Next low float BOMB to EXPLODE
(AWX)$4.30-Book Value $9.70 -Float 2 m -Market Cap $16 m --Profitable company =Next low float BOMB to EXPLODE
(APLIF)$0.52 -Covid PHASE 3 data expected THIS Quarter /MCap $32 m/ Drug partnered with Dr Reddy / UNKNOWN stock
more informations here
http://www.bnnbloomberg.ca/appili-therapeutics-a-david-taking-on-the-covid-19-goliath-and-other-infectious-diseases-1.1627962